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Abstract: Spider silk is an interesting biomaterial for medical applications. Recently, a 
method for production of recombinant spider silk protein (4RepCT) that forms 
macroscopic fibres in physiological solution was developed. Herein, 4RepCT and 
Mersilk
TM (control) fibres were implanted subcutaneously in rats for seven days, without 
any negative systemic or local reactions. The tissue response, characterised by infiltration 
of macrophages and multinucleated cells, was similar with both fibres, while only the 
4RepCT-fibres supported ingrowth of fibroblasts and newly formed capillaries. This in 
vivo study indicates that 4RepCT-fibres are well tolerated and could be used for medical 
applications, e.g., tissue engineering. 
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1. Introduction  
Tissue engineering is an interdisciplinary scientific field that applies the principles of engineering 
and life sciences to develop biological substitutes intended to maintain, restore, or improve tissue 
functions [1], and can arbitrarily be divided into two main principles: 
•  Autologous cells are cultured in vitro and transplanted back into the patient as a cell suspension, 
as a graft, or in a 3D-biodegradable carrier matrix. 
•  A tissue is stimulated and provided the right prerequisites to regenerate in situ by implantation 
of specially designed materials, or the application of substances that regulate cell functions. 
This method is often referred to as guided tissue regeneration. 
In both these approaches biodegradable scaffolds are often used to facilitate the transplantation or 
ingrowth of cells and tissues [2–5]. As the scaffold temporarily replaces the tissue at target, the 
surrounding cells (or the cells transplanted with the matrix) migrate into (out of) the scaffold, 
proliferate, and subsequently form regenerated tissue. One crucial point is to use a scaffold with 
optimal qualities for  e.g., cell adhesion, -migration, -proliferation, and -differentiation, as well as 
porosity, degradation, etc. Furthermore, a material intended for medical applications is obliged to be 
biocompatible, i.e., elicit an appropriate host response reaction in a specific application without having 
toxic or injurious effects on the biological system. Also, the scaffold should allow and promote 
vascularisation. In recent decades, a number of materials have been approved for use as scaffolds, but 
still none can be considered ideal [3].  
The bulk of scaffolds used today can be divided into synthetic polymers (e.g., polylactide/glycolic 
acids) and natural polymers (e.g., collagens, fibronectin, fibrin, silk). Of these, the natural polymers 
probably exhibit the best biomimetic properties [3,6]. However, collagen, fibronectin and fibrin are 
almost exclusively derived from natural sources, with the concomitant risk of residual antigens and/or 
infectious agents[3]. Also, the mechanical stability of these materials is not as good as synthetic 
polymers or silk [6]. Silk is a mechanically impressive proteinaceous fibre that is produced by e.g., 
silkworms and spiders [7,8]. Silkworm silk has been used as a suture material for centuries due to its 
mechanical properties and, more recently it has also been applied for tissue engineering purposes [9]. 
However, native silkworm silk contains a highly immunogenic protein coat (sericin) that causes 
hypersensitivity reactions [8]. Spider silk on the other hand, has no sericin coating and is known to be 
well tolerated when implanted [10,11], but has large scale production problems [12]. Spiders are 
difficult to farm and each individual produces small amounts of silk. Therefore, in order to gain large 
amounts, spider silk has to be produced recombinantly. Most heterologous expression systems 
available have been tested to produce spider silk. However, since the spider silk proteins are large, 
repetitive, and prone to aggregate [12–26], the success has been limited. Produced proteins have 
required the use of harsh solvents for solubilisation and subsequent spinning procedures to form fibres 
[14,16,21–23], or formed microscopic fibres intracellularly [20]. 
Recently, a successful strategy to produce recombinant spider silk protein, 4RepCT, in soluble form 
that self-assembles into macroscopic fibres was presented [27]. These fibres are as strong as 
mammalian tendons [27,28] and can be sterilised by autoclaving without change in properties (MH et 
al, to be published). Unlike many other man-made high performance materials, 4RepCT is produced at Materials 2009, 2                                       
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ambient temperature and pressure using only water as a solvent. In conclusion, 4RepCT is a novel 
protein-based material that has the potential to meet many of the desired features of implantable 
biomaterials, particularly for tissue engineering purposes. In vivo experimental analysis of tissue 
reactions to different substances is a valuable tool to investigate the safety and efficacy of a potential 
scaffold material. This study is the first to evaluate the tissue response to recombinant spider   
silk in vivo. 
2. Results and Discussion 
2.1. Materials 
In this pilot study, the tissue response to recombinant spider silk (4RepCT) implanted 
subcutaneously in rats is evaluated. Each animal received six 4RepCT implants that had been 
subjected to different treatments (see experimental section and Table 1), one Mersilk
TM implant and 
one sham (i.e., an incision is made without inserting an implant).  
Table 1. Different treatments of 4RepCT before implantation. Abbreviations: Dulbecco’s 
Modified Eagle’s Medium (DMEM), and Fetal Bovine Serum (FBS). 
Abbreviation Treatment 
C2  Two EndoTrap columns 
C3  Three EndoTrap columns 
C2M  Two EndoTrap columns, fibres soaked in DMEM  
C3M  Three EndoTrap columns, fibres soaked in DMEM 
C2MS  Two EndoTrap columns, fibres soaked in DMEM and FBS  
C3MS  Three EndoTrap columns, fibres soaked in DMEM and FBS  
 
Endotoxins are a natural part of Gram negative bacteria’s outer membrane, thus endotoxin 
contamination is hard to avoid in Escherichia coli production systems. These small and amphiphilic 
molecules may be hard to eliminate, and are known to be pyrogenic and potent activators of the innate 
immune system [29]. In this study, EndoTrap columns were used to remove endotoxins, and the fibres 
were subjected to an in vitro pyrogen test (IPT) [30,31]. The pyrogenicity of the C2 fibres (including a 
possible inherent pyrogenicity of the fibres themselves) was approximately 0.04–0.8 endotoxin units 
(EU)/mg (MH et al, to be published). Only C2-fibres were tested since these are expected to contain 
higher levels of endotoxin compared to the other 4RepCT-fibers. Since the 4RepCT fibres in this study 
weigh approximately 1.5 mg, the amount of endotoxins on the implanted fibres is well below the 
regulatory limit for medical devices (20 EU) [32].  However, since the IPT test only detects pyrogens 
exposed on the surface of the material, it is possible that endotoxins could be present in the fibre core. 
Such potential residual endotoxins could possibly be reduced by leaching (e.g., in DMEM), by 
removal before fibre formation by passage over an extra Endotrap column (C3), and/or shielded by 
deposition of plasma proteins on the surface of the fibre (by e.g., FBS). To investigate this, 4RepCT 
fibres were subjected to different combinations of these treatments (see experimental section and   
Table 1), and the results are discussed below. Materials 2009, 2                                       
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As a control, Mersilk
TM, made from silkworm silk and clinically used as suture material, was used. 
A comprehensive blinded study performed by Setzen and Williams comparing the tissue response to 
different suture-materials, among these silkworm silk, Vicryl
TM  (polyglycolic acid) and PDS
TM 
(polydioxanone), showed that silk elicited an equivalent response to absorbable and non-absorbable 
materials, when counting the number of foreign body cells surrounding each suture-material [33]. 
Furthermore, they found a significantly higher response to multifilament sutures than monofilaments, 
confirming the influence of surface area-to-volume ratio in induction of an inflammatory response. In 
the present study, care was taken to compare two proteinaceous fibres of similar structure (Figure 1).  
Figure 1. Macroscopic appearance 4RepCT fibres in (a) and of Mersilk
TM in (b). For 
illustration, an undyed Mersilk
TM suture (4-0, Ethicon) was used whereas dyed (black) 
sutures were used for implantation. Scale bars correspond to 0.1 mm. 
 
 
2.2. The normal tissue response to implanted materials 
Host reactions following implantation of biomaterials include injury, blood-material interactions, 
and acute inflammation, followed by a foreign body reaction characterized by chronic inflammation, 
granulation tissue development, and fibrosis/fibrous capsule development [34]. The acute reaction is 
characterized at the histological level by the presence of polymorphonuclear leukocytes and 
macrophages, and usually resolves within one week. However, if the material persists in the tissue, the 
inflammation becomes chronic. The number of polymorphs may decrease and the presence of 
mononuclear cells (most commonly monocytes, lymphocytes and plasma cells) becomes more 
prominent, together with macrophages and multinucleated giant cells present at the implant surface. 
With biocompatible materials the chronic inflammatory phase lasts no longer than two weeks, even 
though the foreign body reaction at the tissue/material interface is present for the lifetime of the 
implant [34]. In addition to the acute and chronic inflammatory reactions, granulation tissue forms and 
is identified by the presence of macrophages, infiltration of fibroblasts and neovascularization of the 
healing tissue. In the present study, the animals carried the implants for seven days, which allowed for 
macroscopic evaluation of the acute inflammatory response and also histological evaluation of the 
tissue at the transition from acute to chronic inflammation. 
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2.3. Macroscopic evaluation 
During the course of the study, all rats remained in good health and gained weight as expected 
(Supplementary Table 1). The recovery from the anaesthesia was rapid and the dermal incisions healed 
normally. The sites of implantation were inspected daily, and no inflammatory signs were noted.  
At explantation, after seven days, the implants were inspected in situ before being removed   
(Figure 2a-c, Table 2). Five of the eighteen 4RepCT implants showed a local erythematous reaction 
surrounding the implants (Figure 2c), while the tissue surrounding five other 4RepCT implants and 
two Mersilk
TM implants showed no redness (Figure 2a, Table 2). The remaining eight 4RepCT 
implants and one Mersilk
TM implant showed an erythematous reaction at one pole of the implant 
(Figure 2b, Table 2). This reaction might be a part of the natural acute phase of the inflammatory 
reaction toward implanted biomaterials [34]. Two of the five implants that received the highest score 
for erythematous reaction (C3MS animal no. 1 and C2MS animal no. 3), later displayed local 
hemorrhage from an injured artery when examined histologically, which may explain the reddening. 
Apart from this, the reddening observed macroscopically could not be explained by inflammatory 
changes, as observed by the histopathological assessment (Table 2, Table 3). 
2.4. Histological evaluation 
Sections of the 4RepCT implants displayed subcutaneously located bundles of acidophilic fibres. 
The surrounding tissues were infiltrated by macrophages and multinucleated giant cells, the latter 
consistent with a foreign-body type reaction. Some implants showed a polar infiltration of cells, as 
exemplified in Figure 3b. In general, in the periphery of the 4RepCT implants, phagocytic cells, 
mainly macrophages but to some extent also multinucleated giant cells, displayed fibre-remnants 
intracellularly and increased cytoplasmic acidophilia. This suggests an ongoing degradation process, 
which was further corroborated by the presence of partially degraded fibres in the periphery of the 
implants, whereas the center of the fibre bundles seemed more intact. From the surrounding tissues, 
thin septae with delicate tubular structures of angioblast-like cells could be seen extending into some 
of the 4RepCT fibre bundles, consistent with formation of new capillaries. In line with this 
observation, erythrocytes were found in the lumen of these tubular structures (Figure 3h). Throughout 
the fibre-bundles, fibroblast-like elongated cells were found in close contact with individual 4RepCT 
fibres (Figure 3g). In most cases, a capsule of loose fibrous tissue, consisting of fibroblasts, fibrocytes, 
collagen fibres, and newly formed blood vessels, surrounded the 4RepCT fibre-bundle. In this capsule, 
some polymorphs and lymphocytes were occasionally observed (Table 3). These cells appeared to 
remain in the capsule or in the surrounding tissue rather than occupying the fibre-bundle. 
 The different preparations (double or triple EndoTrap purification, soaking in DMEM or in DMEM 
and FBS) of the 4RepCT fibres did not result in any obvious difference in host reaction or cellular 
response to the implants (Table 2, Table 3). However, additional and larger studies must be performed 
to draw any further conclusions. Two 4RepCT implants of eighteen could not be found at sectioning 
(Table 3). 
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Figure 2. In vivo macroscopic appearances (graded * to ***) of implants at explantation. 
The rating in Table 2 is exemplified by (A) 4RepCT, degree* (C3 from animal no 1), (B) 
Mersilk
TM, degree ** (from animal no 3), and (C) 4RepCT, degree*** (C3M from animal 
no 1). Scale bars are 1.0 cm. 
 
 
Table 2. Macroscopic appearances (graded * to ***) of all implants (see also Figure 2). 
Implants where the surrounding tissue shows no rubor is indicated by *, slight rubor at one 
pole of the implant is indicated by **, and rubor surrounding the whole implant is 
indicated by ***, see Figure 2 for examples. The implants are listed in the left column and 
the numbers (1-3) in the top row indicate the different rats. Abbreviations; C2, C3, C2M, 
C3M, C2MS, C3MS corresponds to different 4RepCT fibre treatments (see experimental 
section and Table 1). 
 Implant  1  2  3 
C2 * ** ** 
C3 * ** ** 
C2M ***  **  * 
C3M ***  *  * 
C2MS ***  **  *** 
C3MS ***  **  ** 
Mersilk
TM *  *  ** 
Sham *  *  * 
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Table 3. Histopathologic assessment. The implants are listed to the left, for each 
individual. Abbreviations; C2, C3, C2M, C3M, C2MS, C3MS corresponds to the different 
4RepCT fibre treatments (see experimental section and Table 1). Each implant has been 
rated according to the cell numbers/intensity of the lesions; +: low numbers of infiltrated 
leukocytes/mild changes. ++: intermediate numbers of infiltrated leukocytes/moderate 
changes. +++: numerous infiltrated leukocytes/severe changes. 0: not observed/ very low 
numbers of infiltrated leukocytes. nf: implant was not found at histological evaluation.  
-: Absence of implant (sham treated). * Phagocytic cells: macrophages and multinucleate 
giant-cells. ** Capsule: organized granulation tissues around fibres, including fibroblasts, 
fibrocytes, collagen fibres, angioblasts and newly formed capillaries. 
1 Local haemorrhage. 
 
Polymorpho-
nuclear cells 
Phagocytic 
cells * 
Mono-
nuclear 
leukocytes 
Capsule ** 
Granulation 
tissue 
between 
fibres 
Animal 1, implant  
C2 +  +++  ++  +++  +++ 
C3 +  ++  + ++ ++ 
C2M +  ++  +  +++  + 
C3M +  +++  ++  +++  ++ 
C2MS +++  ++  ++  +++  + 
C3MS 0  +++  ++  +++
1  + 
Sham -  -  -  -  - 
Mersilk
TM  + +++  + ++ ++ 
Animal  2, implant   
C2 0  +++  0  +++  + 
C3 +  +++  +  +++  + 
C2M nf  nf  nf  nf  nf 
C3M 0  ++  0  ++  ++ 
C2MS 0  +++  +  +++  + 
C3MS 0  +++  +  +++  ++ 
Sham -  -  -  -  - 
Mersilk
TM  + ++  0 +  + 
Animal 3, implant   
C2 0  +++  ++  +++  +++ 
C3 0  +++  +  +++  +++ 
C2M 0  +++  +  +++  +++ 
C3M 0  +  ++  +++  + 
C2MS +  ++  +++  +++
1  + 
C3MS nf  nf  nf  nf  nf 
Sham -  -  -  -  - 
Mersilk
TM  0 +  +  +++  +++ 
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Figure 3. Microscopic appearances of implants. The Mersilk
TM implant from rat no. 3 is 
shown in (a), (c) and (e). 4RepCT fibre implants are shown in (b), (d) and (f) (C3 from rat 
no. 2), and in (g) and (h) (C2 from rat no. 2). Scale bars are 100 μm in a-g, and 10 μm in h.   
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(a) A fibrous capsule surrounds bundles of regular refringent fibres of the Mersilk
TM 
implant.  (b) A polar infiltrate surrounds the 4RepCT implant, where one side evokes 
practically no response, at the bottom of the figure, while the opposite side, in the upper 
part of the figure, shows a moderate foreign body reaction with macrophages and 
multinucleated giant cells. (c)  Capillaries are present in the fibrous capsule surrounding 
Mersilk
TM (*). Inside of the capsule, cells have populated the implant. (d) The side of the 
4RepCT that evokes almost no inflammatory response is shown. The location of the 
4RepCT implant is indicated by a double edged arrow. (e) The reaction in close contact 
with the Mersilk
TM implant displays macrophages (arrows) and multinucleated giant cells 
(#). (f) The side of the 4RepCT implant that evokes a moderate foreign body response is 
shown. The cell reaction adjacent the 4RepCT implant exhibit macrophages (arrows) and 
multinucleated giant cells (#). (g) The centre of a 4RepCT fibre bundle displays delicate 
septae with elongated cells, resembling fibroblasts, angioblasts and newly formed 
capillaries. The square box (magnified in h) encloses capillaries in the 4RepCT fibre 
bundle. (h) Magnification of square box in (g) shows erythrocytes in the lumen of tubular 
structures indicating capillaries present (and newly developed) in the centre of a 4RepCT 
fibre bundle. 
 
The silkworm silk (Mersilk
TM, dyed black by the manufacturer) fibres were refringent instead of 
acidophilic (Figure 3a). These fibres occupied less space in the tissue and appeared to be more intact 
than the 4RepCT implants. Essentially the same kinds and numbers of cells were found in the tissue 
surrounding the Mersilk
TM and 4RepCT (Table 3), but the phagocytes and macrophages adjacent to the 
fibres were smaller in size and the fibrotic capsule surrounding Mersilk
TM was more dense (Figure 3). 
In the Mersilk
TM fibre bundle, macrophages, multinucleated giant cells, and a few fibroblasts could be 
observed. However, in contrast to the 4RepCT implants, no newly formed capillaries could be 
identified and the infiltration of fibroblasts was much less pronounced in the center of the Mersilk
TM 
implants. 
The sections that contained shams (i.e., no implants) displayed changes in the subcutaneous tissue 
consistent with a normal wound healing reaction, i.e., granulation tissue. Also, some focal areas of 
increased cell density (macrophages, multinucleated giant cells and polymorphonuclear cells) 
surrounding fragments of hair shafts were observed, consistent with foreign body type reaction. 
The tissue surrounding both the 4RepCT and the Mersilk
TM implants were infiltrated by leukocytes, 
rich in macrophages and multinucleated giant cells (Figure 3 a-f). A fibrous capsule surrounded the 
implants, but appeared denser in the case of Mersilk
TM implants. Also, the tissue surrounding some 
implants contained polymorphonuclear cells (9 of 19 implants) and mononuclear leukocytes (16 of 19 
implants), which is indicative of acute and chronic inflammation, respectively (Table 3). The 
histological analysis after one week implantation revealed numerous phagocytic cells, consistent with 
a foreign body reaction with features of both acute and chronic inflammation, which is the natural 
response to any implanted foreign object after one week [34]. Polyacrylamide gel (commonly used 
dermal filler) subcutaneously injected in rats, show a similar histological appearance with 
macrophages, polymorphonuclear leukocytes and a thin fibrous capsule after one week of   
implantation [35].  
Angiogenesis may be an inherent effect of silk-based biomaterials [36,37], and in accordance, 
newly formed capillaries were observed in the tissue surrounding the 4RepCT and the Mersilk
TM Materials 2009, 2                                       
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implants. Neovascularization is a critical factor for successful tissue engineering since it is a 
prerequisite for a continuous support of oxygen, nutrients and biochemical cues to the cells in the three 
dimensional  matrix [37]. Thus, the ability to support the formation of vascularised tissues is a desired 
feature for any material used for tissue engineering purposes. It has also been hypothesized that, like 
growth factors, any biomaterial able to stimulate angiogenesis without amplifying inflammation could 
be effective in stimulating wound healing [36]. The most pronounced histological difference between 
the 4RepCT and the Mersilk
TM implants was the presence of fibroblast-like cells and newly formed 
capillaries in the center of 4RepCT fibre bundles (Figure 3 g, h), indicating that the 4RepCT implants 
are superior in supporting (and perhaps even at promoting) the physiological migration of fibroblasts 
and angioblasts. 
The 4RepCT fibres seemed to be degraded by macrophages, possibly by endocytosis and 
subsequent intracellular proteolysis. Degradation of Mersilk
TM fibres appeared to be more slow, but 
the presence of macrophages engulfing the fibres suggests a similar mechanism of degradation as for 
4RepCT fibres. Mersilk
TM fibres are considered non-degradable since they retain at least 50% of their 
tensile strength after 60 days of implantation [8]. However, the silk fibres will eventually be degraded, 
probably by proteolytic degradation mediated by a foreign body response [8]. In general, implants that 
are degradable show a more intense immunological response than permanent materials  [33].  
2.5. Features of 4RepCT for tissue engineering 
Successful tissue engineering requires a suitable material to use as scaffold. Many different 
materials (natural and synthetic, biodegradable and (semi)-permanent) have been employed, but most 
have proven suboptimal since they are unable to support the regenerating tissue in all aspects needed 
[3]. There are several potential advantages of using recombinant spider silk (4RepCT) as a biomaterial 
for tissue regeneration. First, 4RepCT fibres are mechanically robust and can support the formation of 
new tissue. Second as shown here, the material is biodegradable and will eventually be replaced by the 
host’s own tissue. Third, the three-dimensional structure and morphology of 4RepCT assemblies can 
be tailored to resemble the structure and morphology of the tissue to be replaced. Fourth, 4RepCT is 
recombinantly produced, reducing the risk of contaminating biohazardous components and allowing 
large scale production. Also, the results from this pilot study show that the 4RepCT is biocompatible 
when implanted subcutaneously in vivo. 
3. Experimental Section 
3.1. Production of 4RepCT  
The miniature spider silk protein (4RepCT) was produced in E. coli BL21(DE3) cells (Merck 
Biosciences) using a modified pET vector encoding the fusion protein His6/thioredoxin/His6/thrombin 
cleavage site/4RepCT, as previously described[38]. The cells were grown at +30 °C in kanamycin 
supplemented Luria-Bertani medium to an OD600 of ~1, induced with 0.5 mM isopropyl-β-D-thio-
galactopyranoside, and further incubated for 2 hours at room temperature. Cells were harvested by 
centrifugation at 4,000 g and gently resuspended in 20 mM Tris, pH 8, and frozen at -20 °C.  Materials 2009, 2                                       
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3.2. Protein purification and fibre formation 
After complete cell lysis with lysozyme and DNAseI, the 15,000 g supernatants were loaded on 
columns packed with Ni-sepharose (GE Healthcare, Uppsala, Sweden) and equilibrated with 20 mM 
Tris-HCl, pH 8.0. The columns were washed extensively (20 column volumes (CV)), first with 20 mM 
Tris-HCl, pH 8.0 and subsequently with 20 mM Tris-HCl, 30 mM imidazole, pH 8.0, before bound 
proteins were eluted with 300 mM imidazole. Pooled fractions were dialyzed against 20 mM Tris-HCl, 
pH 8.0 over night and 100 µM CaCl2 was added to the protein samples before being loading onto 
EndoTrap Blue columns (Profos AG, Regensburg, Germany). After the void volume was discarded, 
the flow-through was collected and diluted to a concentration of 1 mg/ml. 4RepCT was released from 
the tags by proteolytic cleavage using a thrombin:fusion protein ratio of 1:1,000 (w/w), and allowed to 
pass over an other Ni-sepharose column (GE Healthcare, Uppsala, Sweden) to remove the tags. The 
solution containing 4RepCT was subsequently allowed to pass one or two additional EndoTrap Blue 
columns before being concentrated in Amicon concentrators and was then allowed to self-assemble 
into fibres as previously described [27]. Each fibre was formed from 1.5 mg protein. Fibres were 
removed from the tubes and washed twice in 20 mM Tris-buffer and twice in sterile water in order to 
remove any traces of the soluble released tags. The fibres were autoclaved for 2 × 15 minutes at  
+121 °C and 2.8 bar in tubes filled with sterile water. The fibres were stored at +4 °C until used.  
3.3. Treatments of protein and fibres 
Fibres were made from protein solutions that in total were allowed to pass over two (C2) or three 
(C3) Endotrap Blue columns. Subsequently the fibres were subjected to one of three different 
treatments, giving the 6 different fibres for implantation: 
1.  Two Endotrap columns, no additional treatment (C2) 
2.  Three Endotrap columns, no additional treatment (C3) 
3.  Two Endotrap columns, soaked in DMEM (Dulbecco’s Modified Eagle’s Medium, Invitrogen 
AB, Lidingö , Sweden) for 30 minutes prior to implantation (C2M) 
4.  Three Endotrap columns, soaked in DMEM for 30 minutes prior to implantation (C3M) 
5.  Two Endotrap columns, soaked in DMEM containing 10% fetal bovine serum (FBS, Invitrogen 
AB, Lidingö, Sweden) for 30 minutes prior to implantation (C2MS) 
6.  Three Endotrap columns, soaked in DMEM containing 10% FBS for 30 minutes prior to 
implantation (C3MS). 
As control-implants, commercially available silkworm silk suture (Mersilk
TM) was used (4-0, 
Perma-hand Seide, Ethicon, Somerville, New Jersey). The appearances of 4RepCT fibres and 
Mersilk
TM sutures are shown in Figure 1. 
3.4. Pyrogen analysis  
The pyrogen content in protein solutions and fibres was measured using an in vitro pyrogen test 
(IPT) (MH, et al. to be published). Briefly, human whole blood was brought into direct contact with 
the 4RepCT fibres (C2) and the release of the pro-inflammatory cytokine IL-1β was measured [30,31]. Materials 2009, 2                                       
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Lipopolysaccharide (LPS) concentration-response curves were derived using LPS from Salmonella 
abortus equi. 
3.5. Subcutaneous implantation in rats 
The study was approved by the ethics committee of animal experiments (Linköpings 
Djurförsöksetiska Nämnd, Linköping, Sweden, Dnr 96-08). Three 8-week old female Wistar rats 
(Rattus norwegicus, Scanbur, Sollentuna Sweden), weighing 159-184 g were included in the study. 
The rats were housed at the animal unit at the University of Linköping, at 25 °C and on a 12-hour-
light-dark cycle. The rats had free access to water and low-fat rodent pelleted diet and were allowed to 
acclimatize for one week prior to the experiment. The rats were weighed on a regular basis (see 
supplementary Table 1). During surgery (implantation of the study materials) the rats were 
anaesthetised by inhalation of isoflurane (Baxter Medical AB, Kista, Sweden) and given Temgesic
® 
0.3 mg/mL (buprenofin 35 μg/kg, Schering-Plough AB, Stockholm, Sweden) by subcutaneous 
injection as analgesia. A subcutaneous injection of 2.5 mL physiological saline (9 mg/mL, Baxter 
Medical AB, Kista Sweden) ensured maintained fluid balance. The back of each rat was shaved and 
swabbed with iodine (0.1%, Pharmaxin Sweden AB, Helsingborg, Sweden) and then four sagital 
incisions (approximately 1 cm long) parallel to the midline were made on each side with a scalpel. By 
blunt dissection with scissors, approximately 1 cm wide subcutaneous pockets were formed. Each 
animal received seven implants (C2, C3, C2M, C3M, C2MS, C3MS and Mersilk
TM) and one sham 
incision, randomly distributed. The implants were 5 cm long and approximately 0.15 mm in diameter 
(Figure 1), rolled up in a bundle. The animals were monitored for local symptoms at the wound area on 
a daily basis. Seven days after implantation the animals were euthanized by an intraperitoneal injection 
of 5 mL sodium penthobarbital (Penthobarbital natrium vet., 60 mg/mL, Apoteket Laboratory 
Products, Sweden). 
3.6. Histological observations 
The dorsal cutis and subcutis was removed from the underlying tissues, and implants with 
surrounding tissues were inspected macroscopically and photographed before samples were excised. 
After excision the implants with surrounding tissue were fixed in 10% buffered neutral formalin for  
2 days, processed for histology and embedded in paraffin.  Sections, 4 μm thick were cut with a 
microtome (Historange Microtome, LKB, Bromma, Sweden) and stained with haematoxylin and eosin 
(H&E) or van Gieson (VG) and mounted in Pertex
® (Histolab, Göteborg, Sweden). Stained sections 
were evaluated using a Nikon Eclipse E600 microscope and images were photographed using a Nikon 
DXM1200 digital camera (Nikon, Tokyo, Japan). The tissue sections were examined and scored 
blindly by a pathologist. 
4. Conclusions  
4RepCT fibres are well accepted when implanted subcutaneously in rats. In particular, the presence 
of newly formed capillaries and fibroblast-like cells in the center of the 4RepCT fibre-bundles already 
after one week implantation indicates that the 4RepCT fibres support the formation of vascularised Materials 2009, 2                                       
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tissue. Further in vivo studies are warranted to fully evaluate the ability of the 4RepCT fibres as a 
scaffold-material for tissue engineering in humans. 
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